Clinical Trials Browser

Phase 2/3 × Mast Cell Activation Disorders × Clear all

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Phase 2/3 Unknown

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic